BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
66.08
-0.06 (-0.09%)
Oct 6, 2026, 10:44 AM EDT - Market open
BridgeBio Pharma Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, BridgeBio Pharma stock has a consensus rating of "Buy" and an average price target of $109.1. The average 1-year stock price forecast is 65.10% higher than the current stock price, while the lowest is $80 (+21.07%) and the highest is $157 (+137.59%).
Price Target: $109.1 (+65.10%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 15 | 16 | 14 | 14 | 14 |
| Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Hold | 1 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 24 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $120 | Buy | Reiterates | $120 | +81.60% | Oct 6, 2026 |
| Barclays | Barclays | Buy Maintains $157 | Buy | Maintains | $157 | +137.59% | Sep 30, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $110 | Buy | Reiterates | $110 | +66.46% | Sep 24, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $130 | Buy | Maintains | $130 | +96.73% | Sep 14, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $96 → $110 | Buy | Maintains | $96 → $110 | +66.46% | Aug 31, 2026 |
Financial Forecast
Revenue This Year
1.03B
from 502.08M
Increased by 104.50%
Revenue Next Year
1.70B
from 1.03B
Increased by 65.29%
EPS This Year
-2.58
from -3.78
EPS Next Year
0.03
from -2.58
EPS and Forward PE are based on non-GAAP adjusted numbers.